PET Scans to Track Activity in Systemic Sclerosis
Uses PET/CT scans to monitor disease activity in adults with systemic sclerosis.
Plain-language title generated from the registry record
Registry title: PET Imaging of Systemic Sclerosis Using FDG and 68Ga-DOTA-Siglec-9
Key facts
- Where
- Turku, FinlandSee the site
Where in Finland
- Turku University Hospital, Turku PET CentreTurku, FinlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Turku University Hospital
- Trial code
- NCT05108857
- Record updated
- 4 December 2024
- Original description
This study evaluates the potential of positron emission tomography (PET)/computed tomography (CT) imaging to monitor disease activity in patients with systemic sclerosis (SSc). PET/CT imaging will focus on two pathological features of SSc, i.e. metabolic activity evaluated by glucose analog 18F-FDG, and expression of inflammation-inducible vascular adhesion protein 1 (VAP-1) evaluated by 68Ga-DOTA-Siglec-9 tracer.Read full original descriptionShow less
PET Imaging of Systemic Sclerosis Using 18F-FDG and 68Ga-DOTA-Siglec-9
This study evaluates the potential of positron emission tomography (PET)/computed tomography (CT) imaging to monitor disease activity in patients with systemic sclerosis (SSc). PET/CT imaging will focus on two pathological features of SSc, i.e. metabolic activity evaluated by glucose analog 18F-FDG, and expression of inflammation-inducible vascular adhesion protein 1 (VAP-1) evaluated by 68Ga-DOTA-Siglec-9 tracer.
Inclusion: Adults with active systemic sclerosis (SSc); Onset of SSc (defined as first non-Raynaud symptom) not more than 5 years ago; Clinically active disease with proximal nailfold capillary abnormalities detected with videocapillaroscopy and/or raised inflammatory markers (CRP or ESR).
Exclusion: History of treatment with, prior to this study, immunosuppressives or disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate, leflunomide, azathioprine, mycophenolate, cyclophosphamide or biologic agents such as anti-TNF inhibitors, abatacept, or rituximab. Hydroxychloroquine is allowed in the history (≥3 months prior to PET study); Intra-articular or parenteral corticosteroids ≤4 weeks prior to PET/CT study; History of or current inflammatory joint disease or autoimmune disease other than SSc; Prostanoids or other vasoactive treatments like phosphodiesterase-5 inhibitors or endothelin receptor antagonists ≤4 weeks prior to PET/CT study (the use of calcium channel inhibitors is allowed); Underage, pregnant, breastfeeding, handicapped or prisoner.